Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-11-20
2007-11-20
Parkin, Jeffrey S. (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S188100
Reexamination Certificate
active
10351641
ABSTRACT:
The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
REFERENCES:
patent: 5122614 (1992-06-01), Zalipsky
patent: 5357041 (1994-10-01), Roberts et al.
patent: 5358934 (1994-10-01), Borovsky et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5656480 (1997-08-01), Wild et al.
patent: 5723129 (1998-03-01), Potter et al.
patent: 5763160 (1998-06-01), Wang
patent: 5843913 (1998-12-01), Li et al.
patent: 5932462 (1999-08-01), Harris et al.
patent: 5968776 (1999-10-01), Klein et al.
patent: 6080724 (2000-06-01), Chassaing et al.
patent: 272858 (1988-06-01), None
patent: 306912 (1989-03-01), None
patent: 578293 (1994-01-01), None
patent: WO91/07664 (1991-05-01), None
patent: WO91/09872 (1991-07-01), None
patent: WO93/14207 (1993-07-01), None
patent: WO96/19495 (1996-06-01), None
patent: WO99/59615 (1999-11-01), None
Lawless, M. K., et al. 1996. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Biochem. 3:13697-3708.
Ausubel, L. J., et al. 1996. Complementary mutations in an antigenic peptide allow for crossreactivity of autoreactive T-cell clones. Proc. Natl. Acad. Sci. USA 93:15317-15322.
Bergmann, C. C., et al. 1996. Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. J. Immunol. 157:3242-3249.
Adams et al., 1985, “Thec-myconcogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice”, Nature 318:533-538.
Alexander et al., 1987, “Expression of the c-myc oncogene under control of an immunoglobulin enhancer in Eμ-myc transgenic mice”, Mol. Cell. Biol. 5:1436-1444.
Fingl & Woodbury, 1975, in “The Pharmacological Basis of Therapeutics”, Ch.1 p.1.
Goff et al., 1981, “Isolation properties of Moloney Murine Leukemia virus mutants: use of rapid assay for release of virion reverse transcriptase”, J. Virol. 62:139-147.
Grosschedl et al., 1984, “Introduction of a μ immunoglobulin gene into the mouse germline: specific expression in lymphoid cells and synthesis of functional antibody”, Cell 38:647-658.
Hammer et al., 1987, “Diversity of Alpha-protein gene expression in mice is generated by a combination of separate enhancer elements”, Science 235:53-58.
Hanahan, 1985, “Heritable formation of pancreatic β-cell tumors in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes”, Nature 315:115-122.
Kelsey et al., 1987, “Species- and tissue-specific expression of human α1-antitrypsin in transgenic mice”, Genes and Dev. 1:161-171.
Kollias et al., 1986, “Regulated expression of HumanAγ-, β-, and hybrid γβ-globin genes in transgenic mice: manipulation of the developmental expression patterns”, Cell 46:89-94.
Krumlauf et al., 1985, “Developmental regulation of α-fetoprotein genes in transgenic mice”, Mol. Cell. Biol. 5:1639-1648.
Macdonald, 1987, “Expression of the pancreatic elastase I genes in transgenic mice”, Hepatology 7:42S-51S.
Magram et al.,1985, “Developmental regulation of a clothed adult β-globulin gene in transgenic mice”, Nature 315:338-340.
Mason et al., 1986, “The hypogonadal mouse: reproductive functions restored by gene therapy”, Science 234:1372-1378.
Matthews et al., 1987, “Interaction between the human T-cell lymphotropic virus type IIIBenvelope glycoprotein gp120 and the surface antigen CD4:role of carbohydrate in binding and cell fusion”, PNAS 84:5424-5428.
Olson et al., 1993, “Concepts and progress in the development of mimetics”, J. Me. Chem. 36:3049.
Ornitz et al., 1986, “Elastase I promoter directs expression of human growth hormone and SV40 T antigen genes to pancreatic acinar cells in transgenic mice”, Cold Spring Harbor Symp. Quant. Biol. 50:399-409.
Pinkert al., 1987, “An albumin enhancer located 10Kb upstream functions along with it promoter to direct efficient, liver-specific expression in transgenic mice”, Genes and Dev. 1:268-276.
Popovic et al., 1984, “Detection, Isolation, and continuous production of cytopathic retrovirus (HTLV-III) from patients with AIDS and Pre-AIDS”, Science 224:497-508.
Readhead et al., 1987, “Expression of a myelin basic protein gene in transgenic shiverer mice: correction of the dysmyelinating phenotype”, Cell 48:703-712.
Rimsky & Matthews, 1998, “Determinants of human Immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides”, J. Virol. 72:986-993.
Shani M., 1985, “Tissue-specific expression of rat myosin light chain 2 gene in transgenic mice”, Nature, 314:283-286.
Sigma Chemical Company, Biochemicals Organic Compounds For Research And Diagnostic Reagents, 1994, p. 1864.
Swift et al., 1984, “Tissue-specific expression of the rat pancreatic elastase I gene in transgenic mice”, Cell 38:639-646.
Weislow et al., 1989, “New Soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity”, J. Natl. Cancer Inst. 81:577-586.
Willey, 1988, “In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity”, J. Virol. 62:139-147.
Lawless et al. 1996, “HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41”. Biochemistry. 35(42):13697-13708.
Wild et al. 1994, “Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection”. Proc Natl Acad Sci U S A. 91(21):9770-9774.
Anwer Mohmed K.
Barney Shawn
Guthrie Kelly I.
Lambert Dennis M.
Merutka Gene
Jones Day
Parkin Jeffrey S.
Trimeris, Inc.
LandOfFree
DNA encoding T-1249 and other viral fusion inhibitor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA encoding T-1249 and other viral fusion inhibitor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA encoding T-1249 and other viral fusion inhibitor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3856825